Table 2. Key active trials combining immunotherapy and radiation therapy in SCLC.

Trial name/NCT number	Phase	Stage/inclusion	ICB agent	Trial design	RT technique/dose	RT and ICB timing
Limited stage
NRG-LU005 NCT03811002	2/3R	Limited stage	Atezolizumab	ChemoXRT +/− concurrent and adjuvant ICB for 12 months	Conventional 45 Gy/30 fractions (BID) or 66 Gy/33 fractions	Concurrent and adjuvant
NCT03540420	2R	Limited stage	Atezolizumab	ChemoXRT +/− adjuvant ICB for 12 months	Conventional 45 Gy/30 fractions (BID)	ChemoXRT first then ICB adjuvant
NCT02046733	2R	Limited stage	Nivolumab and ipilimumab	ChemoXRT +/− consolidation and maintenance IO	Conventional	Adjuvant
NCT02402920	1	Limited or extensive stage (see below)	Pembrolizumab	ChemoXRT + ICB concurrent + adjuvant	Conventional 45 Gy/30 fractions (BID)	Concurrent and adjuvant
Extensive stage
NCT02402920	I	Extensive or limited stage SCLC	Pembrolizumab	Chemotherapy followed by ICB and radiation therapy	Conventional (BID)	Concurrent and adjuvant
Recurrent/relapsed
NCT02402920	2R	Relapsed/recurrent	Tremelimumab and durvalumab	IO alone vs. SBRT followed by IO	SBRT in 3–5 fractions	SBRT first then IO

SCLC, small cell lung cancer; ICB, immune checkpoint blockade; IO, immuno-oncology therapy.